Regimen Options
Last Updated: 10/19/2026 See Details
| Evolent Pathways | Febrile Neutropenic Risk | Emetogenic Risk | References | ||
|---|---|---|---|---|---|
| Locally Advanced / Recurrent / Metastatic | |||||
Systemic Therapy for Use with radiation therapy (RT) |
cisplatin |
Low | High |
|
|
Systemic Therapy Alone |
cemiplimab-rwlc *if curative RT or surgery not feasible* |
Low | Minimal |
|
|
Locally Advanced / Recurrent / Metastatic
Systemic Therapy for Use with radiation therapy (RT)
Evolent Pathways
cisplatin
Febrile Neutropenic Risk
low
Emetogenic Risk
high
References
Systemic Therapy Alone
Evolent Pathways
cemiplimab-rwlc *if curative RT or surgery not feasible*
Febrile Neutropenic Risk
low
Emetogenic Risk
minimal
References
| Regimen | Alternative | References | |||
|---|---|---|---|---|---|
| LOW VALUE REGIMENS (NON-PATHWAY) WITH SUPERIOR ALTERNATIVES | |||||
Locally Advanced / Recurrent / Metastatic |
** cosibelimab-ipdl ** (if curative RT or surgery not feasible) |
Alternatives: cemiplimab-rwlc |
|
||
LOW VALUE REGIMENS (NON-PATHWAY) WITH SUPERIOR ALTERNATIVES
Locally Advanced / Recurrent / Metastatic
Regimen
** cosibelimab-ipdl ** (if curative RT or surgery not feasible)
References